Systematic review indicates daily aspirin use does not reduce colorectal cancer risk — Evidence Review
Published in Cochrane Database of Systematic Reviews, by researchers from West China Hospital of Sichuan University
Researched by
— the AI search engine for science
Table of Contents
A major new review finds that daily aspirin use does not reliably reduce bowel cancer risk in the general population, while increasing the risk of serious bleeding. Most prior studies suggest potential long-term benefits, but results are mixed and risks may outweigh benefits for average-risk individuals, according to the Cochrane review.
- Many earlier randomized trials and meta-analyses reported reduced long-term colorectal cancer incidence and mortality with aspirin, but typically only after 5-10 years of use, and primarily in higher-risk or previously affected individuals; immediate risks such as bleeding were consistently observed across studies 1 2 6 7 12.
- The new review’s focus on average-risk populations and more rigorous exclusion of observational follow-up (where adherence and confounding are less controlled) results in greater uncertainty about long-term benefits, contrasting with earlier studies that suggested broader population benefit 1 3 8.
- Evidence remains stronger for aspirin’s preventive effect in specific high-risk groups (e.g., Lynch syndrome), while recent data raise concerns about potential harm, especially in older adults or those with bleeding risk factors 4 14.
Study Overview and Key Findings
Colorectal cancer prevention has been a major public health focus, with considerable interest in low-cost interventions like aspirin. While aspirin’s role in preventing vascular events is well established, its use for cancer prevention has been debated due to inconsistent evidence on effectiveness and concerns about adverse effects. This new systematic review stands out for its focus on people at average risk for colorectal cancer, its reliance on randomized controlled trial data, and its explicit assessment of both short-term and long-term outcomes. The study also highlights the importance of balancing potential long-term cancer prevention benefits against immediate and well-known risks such as serious bleeding.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | West China Hospital of Sichuan University |
| Journal Name | Cochrane Database of Systematic Reviews |
| Authors | Zhaolun Cai, Yang Meng, Wenming Yang, Yihui Han, Dan Cao, Bo Zhang |
| Population | People at average risk for colorectal cancer |
| Sample Size | n=124,837 |
| Methods | Systematic Review |
| Outcome | Colorectal cancer risk, precancerous polyps, bleeding risk |
| Results | Daily aspirin use likely does not reduce bowel cancer risk. |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus paper database, which includes over 200 million research papers. The following search queries were used to identify relevant literature:
- aspirin bowel cancer prevention effectiveness
- daily aspirin risks cancer outcomes
- aspirin use cancer risk population studies
Below is a summary of key topics and findings from the related literature:
| Topic | Key Findings |
|---|---|
| What are the long-term effects of aspirin on colorectal cancer and overall cancer risk? | - Long-term aspirin use (≥5 years) is linked to reduced colorectal cancer incidence and mortality, especially for proximal colon; benefit increases with duration 1 6 7 8 12. - Modest reductions in overall cancer risk are seen mainly after prolonged use, but findings are less consistent in average-risk groups 3 9 13. |
| Does aspirin reduce colorectal adenomas or benefit high-risk groups? | - Aspirin reduces recurrence of colorectal adenomas in individuals with a history of these lesions; benefit is more pronounced in secondary prevention 2. - Aspirin reduces colorectal cancer risk in Lynch syndrome (hereditary high-risk), but not in all high-risk sporadic adenoma cases 4 5. |
| What are the immediate and long-term risks of daily aspirin use? | - Daily aspirin increases risk of major bleeding, including gastrointestinal and intracranial hemorrhage, with risk apparent from the outset and higher with increasing age or comorbidities 6 7 14. - In older adults, aspirin may accelerate cancer progression and increase cancer mortality 14. |
| How does the evidence differ between population subgroups and study designs? | - Observational studies often show greater and broader cancer risk reductions than randomized trials; confounding and differences in adherence may explain discrepancies 3 8 9. - Benefit-risk balance varies by age, risk factors, and genetic predisposition 4 12 14. |
What are the long-term effects of aspirin on colorectal cancer and overall cancer risk?
Numerous large-scale studies and meta-analyses indicate that long-term (often over 5-10 years) aspirin use can reduce the risk of colorectal cancer incidence and mortality, particularly for cancers in the proximal colon. However, most of these benefits accrue only after extended use, and results are less clear in people at average risk, particularly when assessed in randomized trial settings. The new review’s findings, showing little to no short-term benefit and very uncertain long-term effects in average-risk individuals, are consistent with the timeline of effect seen in earlier research, but highlight uncertainty about the magnitude and reliability of the benefit for the general population.
- Multiple randomized trials show reduced colorectal cancer risk and mortality with long-term aspirin use, especially for proximal colon cancers 1 6.
- Observational and cohort studies report modest reductions in overall cancer risk, but effects are more pronounced for gastrointestinal cancers 3 9 13.
- Evidence from systematic reviews suggests a delayed benefit, with reductions in colorectal cancer incidence and mortality only becoming apparent after a decade or more 12.
- The current review’s focus on short- to medium-term outcomes in average-risk people contrasts with prior studies that included higher-risk or previously affected populations 1 3 12.
Does aspirin reduce colorectal adenomas or benefit high-risk groups?
Aspirin’s effect is more established in secondary prevention—reducing recurrence of colorectal adenomas (precancerous polyps) in individuals with a history of such lesions. Randomized data also support a benefit for people with hereditary risk (Lynch syndrome). In contrast, evidence for prevention in sporadic high-risk adenoma cases is limited, and findings for the general population are inconsistent.
- Meta-analyses of randomized trials show aspirin reduces risk of recurrent adenomas and advanced lesions in people with prior history 2.
- For Lynch syndrome, randomized trials demonstrate a clear reduction in colorectal cancer incidence with long-term aspirin use 4.
- Recent randomized trials in high-risk but non-hereditary populations have not shown significant benefit for adenoma prevention 5.
- The new review’s focus on average-risk individuals further restricts generalizability of these benefits to the general population 1 5.
What are the immediate and long-term risks of daily aspirin use?
The increased risk of serious bleeding, including gastrointestinal and intracranial hemorrhage, is a consistent finding across all major studies. Risk is immediate upon starting treatment and is heightened in older adults and those with predisposing conditions. Additionally, recent evidence suggests that in older populations, aspirin may accelerate the progression of cancer or increase cancer mortality.
- Major bleeding risk is well established, appears early, and increases with dose and age 6 7 14.
- Even low-dose (“baby”) aspirin increases bleeding risk, particularly in the elderly and those with a history of ulcers or bleeding disorders 7 14.
- In older adults (70+), aspirin may be linked to increased incidence and mortality of advanced-stage cancers 14.
- The new review aligns with these findings, emphasizing that bleeding risks outweigh uncertain cancer prevention benefits for average-risk individuals 1 14.
How does the evidence differ between population subgroups and study designs?
Discrepancies between observational studies and randomized trials are notable. Observational studies often report greater and broader reductions in cancer risk associated with aspirin use, but may be affected by confounding and differences in adherence. Randomized trials, especially those focused on average-risk populations, reveal smaller and less certain benefits. The balance of benefits and harms varies significantly depending on age, baseline risk, and genetic predisposition.
- Observational data suggest greater cancer risk reductions compared to randomized trials, possibly due to confounding or healthier user bias 3 8 9.
- Randomized trial data demonstrate more modest or uncertain benefits, especially in average-risk groups 1 5 12.
- Subgroup analyses indicate that benefits may be more prominent in those with genetic predispositions (e.g., Lynch syndrome) or previous adenomas 4 12.
- The new systematic review supports a move toward personalized, rather than population-wide, preventive strategies 1 4 12 14.
Future Research Questions
While the new review provides important clarity on aspirin’s limited role in preventing colorectal cancer among average-risk individuals, several questions remain. Future research is needed to better define which subgroups may benefit, to clarify the long-term balance of risks and benefits, and to investigate the mechanisms by which aspirin might influence cancer outcomes.
| Research Question | Relevance |
|---|---|
| Which genetic or molecular markers predict benefit from aspirin for colorectal cancer prevention? | Identifying predictive markers could enable targeted use of aspirin in individuals most likely to benefit, improving the risk-benefit balance and supporting precision prevention strategies 4 12. |
| How does long-term aspirin use affect cancer incidence and mortality in older adults? | Recent studies suggest potential harm in older populations, making it critical to clarify age-specific risks and benefits to inform clinical recommendations 14. |
| What is the optimal duration and dose of aspirin for cancer prevention? | The minimum effective dose and duration for cancer prevention remain unclear, especially in average-risk groups; more data are needed to minimize harm while maximizing potential benefit 1 6 7 12. |
| Can aspirin prevent other types of cancer beyond colorectal? | Some studies suggest reductions in other gastrointestinal and select solid tumors, but findings are inconsistent and warrant further investigation 3 8 11 13. |
| How do bleeding risks from aspirin vary by individual risk factors? | Understanding the interplay between age, history of ulcers, comorbidities, and aspirin-related bleeding is essential for personalized risk assessment and safe prescribing 7 14. |